← Leaderboards
Dev Priya Arya
Nubad, Llc
$12,646,040
Attributed
$12,646,040
Total exposure
12
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.5M · FY2008–24$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$12,646,040 · 12
By mechanism
R42$7,594,029 · 3
R41$4,654,479 · 8
R15$397,532 · 1
Top collaborators
No co-investigators on record.
Most similar at Nubad, Llc
Same institution · by research overlap
- Sandra Paige Story$5,237,925
- Meredith Newby Spano$252,413
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsAnti-Bacterial AgentsAntibioticsAminoglycosidesBacteriaUnited StatesStructureGrowthSuccessCostLibrariesRibosomesCommunicable DiseasesToxic EffectDesignAntimicrobialAntibiotic ResistanceCombatMultidisciplinaryScreeningDrug DesignInfectionInnovationBacterial Infections
Grant awards (31)
Aminoglycosides with reduced ototoxicity$999,707
R42 · FY2024 · AI · contact PI
Development of peptide nucleic acid antibiotics$998,585
R42 · FY2024 · AI · contact PI
Development of peptide nucleic acid antibiotics-supplement 1$133,089
R42 · FY2024 · AI · contact PI
Development of peptide nucleic acid antibiotics$33,272
R42 · FY2024 · AI · contact PI
Aminoglycosides with reduced ototoxicity$999,707
R42 · FY2023 · AI · contact PI
Development of peptide nucleic acid antibiotics$999,557
R42 · FY2023 · AI · contact PI
Aminoglycosides with reduced ototoxicity$999,986
R42 · FY2021 · AI · contact PI
Development of peptide nucleic acid antibiotics$999,985
R42 · FY2021 · AI · contact PI
Delivery of chemically modified PNA oligomers$473,508
R41 · FY2021 · AI · contact PI
Supplement Request Alain Letou$16,800
R41 · FY2021 · AI · contact PI
Supplement Request LIDIA.AZANKIA$13,475
R41 · FY2021 · AI · contact PI
Aminoglycosides with reduced ototoxicity via miRNA targeting$397,674
R41 · FY2020 · AI · contact PI
Delivery of chemically modified PNA oligomers$299,999
R41 · FY2020 · AI · contact PI
Nucleobase aminosugars with reduced ototoxicity$364,433
R41 · FY2019 · DC · contact PI
Aminoglycosides with reduced ototoxicity via miRNA targeting$300,000
R41 · FY2019 · AI · contact PI
Aminoglycosides with reduced ototoxicity via miRNA targeting$44,940
R41 · FY2019 · AI · contact PI
Aminoglycosides with reduced ototoxicity via miRNA targeting$12,288
R41 · FY2019 · AI · contact PI
Nucleobase aminosugars with reduced ototoxicity$305,919
R41 · FY2018 · DC · contact PI
Screening the Ribosome for New Target Sites$325,000
R41 · FY2017 · AI · contact PI
Aminoglycosides with reduced ototoxicity$300,000
R41 · FY2017 · AI · contact PI
Screening the Ribosome for New Target Sites$325,000
R41 · FY2016 · AI · contact PI
Aminoglycosides with reduced ototoxicity$300,000
R41 · FY2016 · AI · contact PI
A Rapid Assay for RNA Targeted Drugs$663,747
R42 · FY2015 · GM · contact PI
Development of Peptide Antibiotic Nucleic Acids$299,600
R41 · FY2015 · AI · contact PI
A Rapid assay for RNA targeted drugs: Instrumentation Supplement$81,648
R42 · FY2015 · GM · contact PI
A Rapid Assay for RNA Targeted Drugs$684,746
R42 · FY2014 · GM · contact PI
Development of Peptide Antibiotic Nucleic Acids$295,755
R41 · FY2014 · AI · contact PI
Targeting RNA conformation for drug development$294,583
R41 · FY2012 · GM · contact PI
A novel assay for RNA targeted drugs$285,505
R41 · FY2011 · GM · contact PI
Development of Ets2-Inhibitors$175,156
R15 · FY2009 · CA · contact PI
Development of Ets2-Inhibitors$222,376
R15 · FY2008 · CA · contact PI